BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 37471144)

  • 1. The predominant PAR4 variant in individuals of African ancestry worsens murine and human stroke outcomes.
    Denorme F; Armstrong ND; Stoller ML; Portier I; Tugolukova EA; Tanner RM; Montenont E; Bhatlekar S; Cody M; Rustad JL; Ajanel A; Tolley ND; Murray DC; Boyle JL; Nieman MT; McKenzie SE; Yost CC; Lange LA; Cushman M; Irvin MR; Bray PF; Campbell RA
    J Clin Invest; 2023 Sep; 133(18):. PubMed ID: 37471144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The protease-activated receptor 4 Ala120Thr variant alters platelet responsiveness to low-dose thrombin and protease-activated receptor 4 desensitization, and is blocked by non-competitive P2Y
    Whitley MJ; Henke DM; Ghazi A; Nieman M; Stoller M; Simon LM; Chen E; Vesci J; Holinstat M; McKenzie SE; Shaw CA; Edelstein LC; Bray PF
    J Thromb Haemost; 2018 Dec; 16(12):2501-2514. PubMed ID: 30347494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protease-activated receptor-4 (PAR4) variant influences on platelet reactivity induced by PAR4-activating peptide through altered Ca
    Morikawa Y; Kato H; Kashiwagi H; Nishiura N; Akuta K; Honda S; Kanakura Y; Tomiyama Y
    Thromb Res; 2018 Feb; 162():44-52. PubMed ID: 29289806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PAR4 Platelet Thrombin Receptor Variant rs773902 does not Impact the Incidence of Thrombotic or Bleeding Events in a Healthy Older Population.
    Selvadurai MV; Riaz M; Xie S; Tonkin AM; McNeil JJ; Lacaze P; Hamilton JR
    Thromb Haemost; 2022 Jul; 122(7):1130-1138. PubMed ID: 34852379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race.
    Edelstein LC; Simon LM; Lindsay CR; Kong X; Teruel-Montoya R; Tourdot BE; Chen ES; Ma L; Coughlin S; Nieman M; Holinstat M; Shaw CA; Bray PF
    Blood; 2014 Nov; 124(23):3450-8. PubMed ID: 25293779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic Variant in Human PAR (Protease-Activated Receptor) 4 Enhances Thrombus Formation Resulting in Resistance to Antiplatelet Therapeutics.
    Tourdot BE; Stoveken H; Trumbo D; Yeung J; Kanthi Y; Edelstein LC; Bray PF; Tall GG; Holinstat M
    Arterioscler Thromb Vasc Biol; 2018 Jul; 38(7):1632-1643. PubMed ID: 29748334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A function-blocking PAR4 antibody is markedly antithrombotic in the face of a hyperreactive PAR4 variant.
    French SL; Thalmann C; Bray PF; Macdonald LE; Murphy AJ; Sleeman MW; Hamilton JR
    Blood Adv; 2018 Jun; 2(11):1283-1293. PubMed ID: 29884748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial.
    Tricoci P; Neely M; Whitley MJ; Edelstein LC; Simon LM; Shaw C; Fortina P; Moliterno DJ; Armstrong PW; Aylward P; White H; Van de Werf F; Jennings LK; Wallentin L; Held C; Harrington RA; Mahaffey KW; Bray PF
    Blood Cells Mol Dis; 2018 Sep; 72():37-43. PubMed ID: 30055940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced potency of prasugrel on protease-activated receptors following bivalirudin treatment for PCI as compared to clopidogrel.
    Kimmelstiel C; Stevenson R; Nguyen N; Van Doren L; Zhang P; Perkins J; Kapur NK; Weintraub A; Castaneda V; Kuliopulos A; Covic L
    Thromb Res; 2019 May; 177():59-69. PubMed ID: 30851630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the
    Ningtyas D; Thomson RJ; Tarlac V; Nagaraj SH; Hoy W; Mathews JD; Foote SJ; Gardiner EE; Hamilton JR; McMorran BJ
    Front Genet; 2020; 11():432. PubMed ID: 32425989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Platelet Function Modulator of Thrombin Activation Is Causally Linked to Cardiovascular Disease and Affects PAR4 Receptor Signaling.
    Rodriguez BAT; Bhan A; Beswick A; Elwood PC; Niiranen TJ; Salomaa V; ; Trégouët DA; Morange PE; Civelek M; Ben-Shlomo Y; Schlaeger T; Chen MH; Johnson AD
    Am J Hum Genet; 2020 Aug; 107(2):211-221. PubMed ID: 32649856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of PAR4 numbers on the surface of human platelets: no effect of the single nucleotide polymorphism rs773902.
    Li S; Tarlac V; Christanto RBI; French SL; Hamilton JR
    Platelets; 2021 Oct; 32(7):988-991. PubMed ID: 32819173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protease-Activated Receptor 4 Variant p.Tyr157Cys Reduces Platelet Functional Responses and Alters Receptor Trafficking.
    Norman JE; Cunningham MR; Jones ML; Walker ME; Westbury SK; Sessions RB; Mundell SJ; Mumford AD
    Arterioscler Thromb Vasc Biol; 2016 May; 36(5):952-60. PubMed ID: 26966273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human and mouse PAR4 are functionally distinct receptors: Studies in novel humanized mice.
    Renna SA; Michael JV; Kong X; Ma L; Ma P; Nieman MT; Edelstein LC; McKenzie SE
    J Thromb Haemost; 2022 May; 20(5):1236-1247. PubMed ID: 35152546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of protease-activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood.
    French SL; Arthur JF; Lee H; Nesbitt WS; Andrews RK; Gardiner EE; Hamilton JR
    J Thromb Haemost; 2016 Aug; 14(8):1642-54. PubMed ID: 26878340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of plasmin-induced protease-activated receptor 4 activation in platelets.
    Mao Y; Jin J; Daniel JL; Kunapuli SP
    Platelets; 2009 May; 20(3):191-8. PubMed ID: 19437337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ATP-gated P2X1 receptor plays a pivotal role in activation of aspirin-treated platelets by thrombin and epinephrine.
    Grenegård M; Vretenbrant-Oberg K; Nylander M; Désilets S; Lindström EG; Larsson A; Ramström I; Ramström S; Lindahl TL
    J Biol Chem; 2008 Jul; 283(27):18493-504. PubMed ID: 18480058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of protease-activated receptor (PAR) 1 and PAR4 signaling in human platelets by compartmentalized cyclic nucleotide actions.
    Bilodeau ML; Hamm HE
    J Pharmacol Exp Ther; 2007 Aug; 322(2):778-88. PubMed ID: 17525299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of race-dependent platelet activation through the protease-activated receptor-4 and Gq signaling axis.
    Tourdot BE; Conaway S; Niisuke K; Edelstein LC; Bray PF; Holinstat M
    Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2644-50. PubMed ID: 25278289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling.
    Kim S; Foster C; Lecchi A; Quinton TM; Prosser DM; Jin J; Cattaneo M; Kunapuli SP
    Blood; 2002 May; 99(10):3629-36. PubMed ID: 11986217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.